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a b s t r a c t
Obesity is a risk factor for developing type 2 diabetes and cardiovascular disease and has quickly become
a worldwide pandemic with few tangible and safe treatment options. Although it is generally accepted
that the primary cause of obesity is energy imbalance, i.e., the calories consumed are greater than are
utilized, understanding how caloric balance is regulated has proven a challenge. Many “distal” causes of
obesity, such as the structural environment, occupation, and social inﬂuences, are exceedingly difﬁcult to
change or manipulate. Hence, molecular processes and pathways more proximal to the origins of obesity
—those that directly regulate energy metabolism or caloric intake—seem to be more feasible targets for
therapy. In particular, nitric oxide (NO) is emerging as a central regulator of energy metabolism and body
composition. NO bioavailability is decreased in animal models of diet-induced obesity and in obese and
insulin-resistant patients, and increasing NO output has remarkable effects on obesity and insulin
resistance. This review discusses the role of NO in regulating adiposity and insulin sensitivity and places
its modes of action into context with the known causes and consequences of metabolic disease.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The obesity epidemic
The recent increase in the prevalence of obesity is cause for
alarm. The Centers for Disease Control and Prevention estimate
that, from 1962 to 2010, obesity prevalence increased from 13 to
36%. As of 2008, approximately 1.5 billion adults age 20 years or
older were overweight, and 10% were obese [1]; more recent data
from the United States indicate that 433% of adults and 17% of
children are obese [2]. This has led to a dramatic increase in
prediabetic states. For example, current estimates indicate that
one-third of the population in the United States meets the criteria
for prediabetes [3,4], and, in addition to type 2 diabetes (T2D),
obesity is closely associated with comorbidities such as cardiovas-
cular disease, hypertension, atherosclerosis, stroke, and cancer [5].
Hence, the current high prevalence of obesity is likely to have a
considerable impact on worldwide health. In addition, the eco-
nomic burden of obesity is substantial and accounts for an
estimated $147 billion per year in health care costs [6]. The
problem has become so severe that, in 2013, the American Medical
Association House of Delegates declared obesity a disease.
The principal cause of obesity is energy imbalance: the calories
consumed are greater than those utilized by bodily processes,
e.g., breathing, digestion, thermogenesis [7]. Indeed, the average
consumption of calories in the United States has increased by
4200 kcal/day per person, which is partly attributable to the
abundance of affordable, widely marketed, energy-dense foods
[8–11]. Nevertheless, evidence suggests that the balance between
calorie intake and energy expenditure is complex and regulated by
many factors. Exposure to increasingly obesogenic environments
has been suggested to promote not only overeating, but inactivity
as well. For example, the human environment is fraught with both
chemical and structural “obesogens.” These include, but are not
limited to, pollutants that promote adiposity and insulin resistance
[12–21]; lack of structural features of the built environment that
promote an active lifestyle, such as easy access to parks, sidewalks,
and bike paths [22–24]; and the night/day cycles in the natural
environment of the individual, which can be altered in those
having certain occupations [25–27]. Moreover, the genetic makeup
of individuals shows strong associations with the predisposition to
become obese [28–30].
Many of these factors inﬂuence body composition in an indirect
or distal manner and thus could be considered “distal causes” of
obesity (Fig. 1). Intervening to address these distal causes is
exceedingly difﬁcult. For example, changing the structural envir-
onment would probably entail departing from particular types of
communities or neighborhoods. Similarly, living under favorable
day–night cycles is impossible for workers in some occupations.
Even weight loss via caloric restriction faces difﬁculties, including
an evolution-engendered guard against low fat mass [7,31] and
the propensity of the body to increase caloric efﬁciency during
dieting [32,33]. The intransigency of these problems has led to a
search for causes more proximal to obesity, which may be tangible
targets for antiobesity therapies.
Metabolic pathways known to regulate obesity
Understanding the mechanisms that promote adiposity and
insulin resistance is critical to stem the growing tide of metabolic
disease. In particular, the development of therapies for obesity
and T2D requires a better understanding of the biochemical
pathways that regulate metabolism and body composition. As a
ﬁrst principle, energy balance must be considered to understand
how changes in body composition could occur. Any effective
obesity treatment must decrease energy intake, increase energy
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Fig. 1. Distal and proximal causes of obesity. Graphical illustration of the common
causes of, or factors that contribute to, obesity: inﬂuencing factors distal to the
disease, such as policy as well as structural and chemical “obesogens” of the built
and social (cultural) environment, may contribute to the prevalence of obesity.
Funding for obesity research, dietary guidelines, physical education policies, and
sidewalk standards are examples of potential inﬂuences related to policy, which is
most distal to the actual disease. The built environment, which comprises places
created or modiﬁed by people—i.e., where individuals work, their transportation
systems, and life outside their homes—is another cause distal to obesity. The social
or cultural environment includes those family or cultural inﬂuences that affect
behavioral activity, occupation (which may involve shift work), and social and
media norms, all of which could affect eating habits and physical activity. Lastly,
direct mechanisms that control hunger, satiety, energy expenditure, and nutrient
absorption are proximal causes of obesity. These proximal causes, which are
regulated by nitric oxide, could be more tangible targets for treating obesity and
diabetes compared with distal inﬂuences and causes.
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expenditure, or both. Nitric oxide (NO) plays an important role in
many of these proximal causes of obesity, which are discussed in
turn below.
Hunger and satiety
The central nervous system regulates caloric intake and the
feeling of satisfaction or fullness after a meal, i.e., satiety. This
regulation is dependent on neural and endocrine inputs that can
be divided into short- and long-term control systems. Release of
cholecystokinin (CCK) in combination with neural signaling in
response to gut distension is a potent signal of satiety and triggers
an end to feeding [34]. The adipose tissue-derived hormone leptin
is crucial to integrate the melanocortin neuronal circuit of the
hypothalamus with the energy stores of the body [34–36]. In
addition to leptin, neuropeptide Y directly affects feeding behavior,
metabolism, and body composition [37,38]; and corticotropin-
releasing hormone, growth-hormone-releasing hormone, galanin,
and ghrelin, some of which are expressed in both the stomach and
the brain, function in hunger and satiety signaling [39]. The
neurotransmitters norepinephrine, dopamine, and serotonin are
also important in central energy balance [34,36], and inhibiting
their reuptake is a strategy employed by use of drugs such as
sibutramine, which have proven effective but have side effects
such as increased blood pressure and heart rate [40]. Other drugs
shown to be effective in decreasing energy intake by suppressing
appetite are reviewed elsewhere [7,41,42].
Nutrient absorption
Targeting nutrient absorption in the gut may be an effective
obesity therapy. Signals from the gut released postprandially are
important not only in regulating food intake, but also in digestion
and nutrient absorption. Ghrelin and CCK, as well as peptide YY,
glucagon-like peptides 1 and 2, gastric inhibitory peptide, and
corticotropin-releasing factor, function to regulate both signaling
and digestion [39,43,44]. Inhibition of gastric and pancreatic
lipases via orlistat treatment decreases triglyceride hydrolysis,
inhibits absorption of ingested fat by 30%, and contributes to a
caloric deﬁcit of approximately 200 calories per day [45]. As with
neurotransmitter reuptake inhibitors, orlistat promotes weight
loss; however, side effects caused discontinuation of the medica-
tion in many patients [40].
Energy expenditure
The largest contributor to obligatory energy expenditure is the
basal metabolic rate (BMR), which is deﬁned as the resting energy
expenditure at thermoneutrality in the unfed state [46]. BMR
includes cellular turnover, repair and basic functions (e.g., main-
tenance of ion gradients, transmembrane metabolite transfer), basal
synthetic reactions (e.g., RNA, DNA protein synthesis), and mito-
chondrial proton leak; it also includes obligatory thermogenesis (e.
g., digestion and absorption) [7,46]. Mitochondria are central to the
regulation of energy expenditure, and targeting their activity has
been a prospect for obesity therapies for decades [47–49]. Therapies
that mimic physiological, antiobesogenic effects are likely to prove
most effective. For example, overexpression of uncoupling protein 1
(UCP1), which increases substrate utilization and electron transport
chain turnover, in white adipose tissue [50] or skeletal muscle [51]
can prevent diet-induced obesity in mice, suggesting that uncou-
pling of oxidative phosphorylation in these two organs is sufﬁcient
to regulate body composition. Brown fat, which expresses relatively
high levels of UCP1, is an exciting target for therapy. Despite the low
amounts of brown fat in humans, as little as 50 g of brown fat has
been estimated to be capable of utilizing up to 20% of basal caloric
needs [52]; and mice with genetically reduced brown adipose tissue
(BAT) mass are prone to obesity [53]. The recent discovery that
adult humans maintain active depots of BAT [54,55], in conjunction
with the identiﬁcation of UCP2 and UCP3 in the skeletal muscle and
other tissues [56,57], suggests that enhancement of mitochondrial
activity may hold promise for combatting obesity.
The ﬁnding that adipocytes in some white adipose tissue depots
can be programmed to become similar to brown adipose tissue has
further invigorated research into understanding the role of adipose
tissue in systemic metabolism. A general idea is to increase mitochon-
dria and UCP1 in white adipose tissue, which could promote a higher
BMR. Several molecular targets have been identiﬁed, with peroxisome
proliferator-activated receptor (PPAR)-γ-coactivator-1α (PGC-1α)
being of critical importance [58]. PGC-1α is a known regulator of
energy metabolism and of mitochondrial biogenesis [59] and has been
shown to induce many of the characteristic brown fat traits in white
adipocytes in vitro [58]. Additionally, recent studies have identiﬁed
secreted proteins that stimulate brown adipocyte thermogenesis and
recruit brown (or beige) adipocytes to white adipose tissue [60,61].
How can factors proximal to the cause of obesity be modulated
to stem the tide of the obesity epidemic? Emerging evidence
suggests that changes in vascular function could regulate meta-
bolic homeostasis, and many studies show that the gaseous
signaling molecule NO may play a pivotal role in regulating
systemic metabolism, body composition, and insulin sensitivity.
In the sections that follow, we discuss NO, how it is regulated by
dietary conditions and obesity, and its known effects on physiol-
ogy, metabolism, and adiposity.
Nitric oxide—endogenous formation and general modes
of biological action
Nitric oxide and related nitrogen oxides have emerged as
critical regulators of cell and tissue function [62]. The potency of
NO was perhaps ﬁrst realized after its inhalation by Sir Humphrey
Davy, who nearly died from the self-experiment and after which
he vowed to “never design again … so rash an experiment” [63].
Nearly two centuries later, identiﬁcation of the cardiovascular
processes controlled by NO led to the Nobel Prize in Physiology
or Medicine in 1998. Nevertheless, the pleiotropy of NO continues
to unfold, and we are now beginning to appreciate the deeper
aspects of its impact on metabolism.
Generation of NO
The most common route of NO production is through the
action of the nitric oxide synthase (NOS) family of enzymes
[62,64]. NOS enzymes catalyze NADPH- and O2-dependent oxida-
tion of L-arginine to L-citrulline, producing NO in the process. Such
synthesis of NO depends on the availability of cofactors such as
FAD, FMN, and tetrahydrobiopterin (BH4), as well as the prosthetic
group heme [65].
The three isoforms of NOS generate NO at different rates [62].
The NOS3 enzyme (commonly called endothelial NOS or eNOS) is
most abundant in the vascular endothelium, but has also been
found in neurons, epithelial cells, and cardiomyocytes [66] as well
as adipocytes [67,68] and hepatocytes [69–71]. It produces rela-
tively low quantities of NO, and its activity is controlled by Ca2þ
and calmodulin, posttranslational modiﬁcations [72,73], and phy-
sical forces such as shear stress [74,75]. NOS1 (frequently called
neuronal NOS or nNOS) is also a Ca2þ/calmodulin-dependent
isoform that can be activated by agonists of the N-methyl-D-
aspartate receptor [75]. It is expressed mostly in neurons, skeletal
muscle, and epithelial cells. Finally, NOS2 (also termed inducible
NOS or iNOS), which has the highest capacity to generate NO, is
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expressed in multiple cell types in response to inﬂammatory
stimuli [75,76]. The results of some studies also suggest a
mitochondria-localized NOS isoform [77,78]; however, the speciﬁc
contribution of this isoform remains unclear. In addition to
posttranslational modiﬁcations and substrate and cofactor avail-
ability, NOS activity is regulated by its localization within cells and
by interactions with itself and other proteins [75].
Additionally, NO can be produced endogenously from the more
oxidized nitrogen oxide, nitrite. Reduction of nitrite to NO is
increased under acidic and hypoxic conditions, with the reduction
occurring enzymatically by heme proteins such as deoxyhemoglo-
bin or deoxymyoglobin [79]. The therapeutic potential of dietary
or pharmacological nitrite is supported by multiple studies
describing improvements in reperfusion injury after myocardial
infarction, in pulmonary hypertension, and injury after organ
transplantation [80].
Biochemical properties of NO
NO is a free radical of rather limited biological reactivity. The
endogenous half-life of NO has been found to be in the range of
2 ms to 42 s and appears to depend on the availability of
reactants [81]. NO primarily reacts with ferrous iron (Fe2þ) and
with other radical species; such reactions form the basis for nearly
all of the biological effects of NO. The highest afﬁnity interactions
of NO are with metalloproteins such as soluble guanylate cyclase
(sGC), cytochrome c oxidase, and hemoglobin; NO also reacts with
nonheme iron. Reaction of NO with Fe2þ results in the formation
of a coordinate bond, which is termed a nitrosyl adduct (i.e.,
nitrosylation). The presence of free radicals such as superoxide
(O2d) [82–85] changes the fate of NO: once reacted, it forms
peroxynitrite [82,84,85] and can no longer bind to ferrous heme
[86]. Peroxynitrite and reactive species derived from it (e.g.,
nitrogen dioxide) are important in inﬂammatory responses [85]
and can modulate cell signaling [87–90], in part by promoting the
oxidation or nitration of a broad range of biomolecules [62].
The NO molecule can also react directly with O2, which itself is
a free radical possessing two unpaired electrons in different πn
antibonding orbitals [91]. The reactions of NO with O2 commonly
underlie the mechanisms by which S-nitrosation or S-oxidation of
protein side chains occurs. In addition, NO can react directly with
thiyl radicals, forming a nitroso covalent bond between NO and
the thiol (termed S-nitrosation or S-nitrosylation). Cysteinyl thiols
of glutathione and proteins are among the most recognized and
studied targets of reactive nitrogen species (RNS). Reaction of
RNS with thiols results in the formation of S-nitrosothiols,
S-glutathiolated species, and oxidized cysteinyl residues [92]. Such
modiﬁcations can lead to transient changes in enzyme activity,
providing redox switches that can be modulated by addition or
removal of the modiﬁcations [93].
General physiological roles of NO
NO has multiple biological actions and can regulate physiology
acutely or lead to long-term changes in cell function. The pleiotropic
roles of NO include the regulation of long-term synaptic transmis-
sion, learning, memory, platelet aggregation, leukocyte–endothelial
interactions, immune function, and angiogenesis and arteriogenesis
(for review, see [94]). However, NO is most well known as a potent
regulator of blood ﬂow and was originally termed endothelial-
derived relaxing factor (EDRF). The story unfolded from Furchgott
and Zawadzki's initial discovery that endothelial cells control
acetylcholine-induced relaxation of smooth muscle [95]. A few
years later, NO was identiﬁed as the key endothelium-derived
molecule promoting vasodilation: NO synthesized by NOS in the
endothelium diffuses into the vessel wall where it activates sGC in
vascular smooth muscle; this leads to a rise in cyclic GMP (cGMP)
and elicits relaxation of the vessel [96–102]. However, it readily
became apparent that different isoforms of NOS have different
physiological functions. For example, NOS3 and NOS1 were found to
have distinct roles in regulating microvascular tone [103]; NOS1
activity in the medulla and hypothalamus is important for systemic
regulation of blood pressure [104–107]; and the nitrergic nerves
containing NOS1 are responsible for penile erection [99,108]. Over-
all, NO derived from the integration of NOS3 and NOS1 activities
plays key roles in regulating systemic blood pressure and acutely
regulating organ blood ﬂow, whereas NOS2-derived NO species are
most well recognized for their impact on pathogen killing and
inﬂammatory processes [82].
Another key function of NO is the regulation of mitochondrial
respiration. Acutely, NO inhibits respiration by binding and inhibit-
ing cytochrome c oxidase. Modulation of respiration by NO is
dependent on both mitochondrial activity and the O2 level
[109,110]. In addition, NO directly regulates the binding and release
of oxygen with hemoglobin [111] and is able to increase blood ﬂow
at sites of very low oxygen concentrations [112]. Thus, a key
function of NO is to modulate O2 gradients in cells and tissues by
regulating hemoglobin action and by inhibiting O2 consumption in
respiring mitochondria [81]. Chronic exposure to relatively high
levels of NO results in mitochondrial biogenesis [113–115], which
could reprogram a cell or tissue to have a higher metabolic capacity.
NO bioavailability is diminished in obese and diabetic states
NO bioavailability is decreased in animal models of obesity and
diabetes [116,117] and in obese and diabetic humans [118,119].
Because its bioavailability is dependent upon the balance between
its generation and its degradation, diminished levels of NO in
obese states may be due to decreased expression of NOS, impair-
ments in NOS activity, or the reaction of NO with reactive species
(e.g., superoxide) (Fig. 2). These are discussed in turn below.
NOS expression changes in obesity
A primary mechanism by which NO bioavailability could be
decreased is via diminished expression of NOS enzymes (Fig. 2A). In
particular, lower NOS3 abundance is found in both adipose tissue
and skeletal muscle of obese humans and rodents [120–124].
Factors associated with obesity and diabetes—including certain
vascular hemodynamic forces, oxidized phospholipids, oxidized
LDL, high levels of insulin, and lack of exercise—can also regulate
NOS3 expression [125–129]. In multiple studies, tumor necrosis
factor-α (TNFα), which is increased in obesity and implicated in the
etiology of insulin resistance [130], was shown to downregulate
NOS3 expression and abundance [123,131–134] by decreasing the
stability of NOS3 mRNA [135,136], effectively shortening its half-life
[137]. This destabilization of the NOS3 message was due, at least in
part, to upregulation of elongation factor 1-α1 [138].
Acutely, TNFα increases NOS3 activity [139], most likely via
activation of the phosphoinositide 3-kinase (PI3K)–Akt [140] and
sphingomyelinase/sphingosine-1-phosphate pathways [141,142].
Such diametrically opposite acute versus chronic effects of TNFα
appear to suggest the existence of negative feedback loops that
sense high levels of NO, leading to downregulation of NOS3.
Indeed, NO donors downregulate NOS3 expression both in vitro
and in vivo, which may involve cGMP and/or S-nitros(yl)ation of
NF-κB [143,144]. A small, 27-nt RNA has also been shown to be an
effective feedback regulator of NOS3 [145]. Whether such small
RNAs or miRNAs that regulate NOS expression are induced with
obesity is currently unclear.
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Notable changes in the abundance of other NOS isoforms also
occur in obesity. The NOS2 enzyme increases in abundance in
pancreatic β cells [146], aorta [147], skeletal muscle [148], liver
[149,150], and adipose tissue [151–153] of obese rodents. In
adipose tissue, the majority of NOS2 is derived from inﬁltrating
bone marrow-derived macrophages that display a proinﬂamma-
tory phenotype [151–153]. Also, high levels of TNFα increase NOS2
in adipocytes, which appears to downregulate UCP2 [154]; hence,
this mechanism could contribute to decreases in white adipose
tissue energy expenditure. In the ventromedial hypothalamus,
which controls energy intake, diet-induced obesity was associated
with lower numbers of NOS1-expressing cells [155]. In the aorta,
however, NOS1 was increased in abundance in mice fed a high-fat
diet. The induction of NOS1 was demonstrated to be due to leptin
stimulation [156] and may partially compensate for the loss of
NOS3-mediated vasodilatory action that typically occurs in obese,
insulin-resistant states.
Changes in NOS3 activity in obesity
Beyond changes in expression, the NO-producing activity of
NOS3 is diminished in metabolic disease (Fig. 2B). In addition to
the required substrates, calcium, and cofactors, the activity of
NOS3 is regulated by protein–protein interactions and by several
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Fig. 2. Mechanisms for decreased endothelial-derived NO in obesity and diabetes. Schematic of changes in NOS3 or NO. (A) Decreased NOS3 expression commonly occurs in
obese and diabetic states. The mechanisms proposed for diminished expression include TNFα-mediated destabilization of NOS3 mRNA, which may involve eEF1A1. High
levels of NO may regulate NOS3 abundance through cGMP-mediated or via NF-κB–SNO feedback regulatory pathways. A small 27-nt RNA regulates NOS3 expression also,
although it is not known whether this mechanism is invoked in obesity or diabetes. (B) Decreased NOS3 activity in obesity and diabetes is largely attributed to insulin
resistance, which may be mediated by free fatty acid (FFA)-induced activation of TLR2, TLR4, and NF-κB. In addition, activation of PKCβII may diminish Akt signaling, which
normally promotes phosphorylation of NOS3 on Ser1177. Phosphorylation at this site increases NO output by the enzyme. Hyperglycemia may also lead to increased
O-GlcNAcylation of NOS3, which decreases Ser1177 phosphorylation and inhibits its activity. In addition, conditions leading to obesity promote upregulation of Cav-1, which
is a negative regulator of NOS3, and ceramide accumulation disrupts the NOS3–Akt–HSP90 complex, diminishing activity of the enzyme. (C) NOS3 may also be uncoupled or
NO quenched in obese and diabetic states. Diminished levels of substrates and cofactors, such as L-arginine or BH4, lead to uncoupling of the enzyme, which is commonly
associated with the presence of NOS3 monomers rather than dimers and can produce superoxide instead of NO. Endogenous inhibitors of NOS3 such as ADMA are also
increased in obese conditions and can promote NOS uncoupling. Elevated production of reactive oxygen species such as superoxide can quench NO and result in its oxidation
to highly reactive peroxynitrite, which damages biomolecules and can oxidize BH4 to BH2.
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posttranslational modiﬁcations [94,157,158]. A high-fat diet was
shown to upregulate caveolin-1, a negative regulator of NOS3
[159,160], in the aorta of obese rats [161]. Furthermore, ceramide
(which is increased in obesity [162]) promotes disruption of the
eNOS–Akt complex from HSP90 [163], which normally increases
NOS3 activity by promoting displacement of caveolin-1 from
NOS3 [164].
Conditions of obesity have profound effects on NOS3 phosphor-
ylation. In particular, NOS3 phosphorylation at serine 1177 (S1177;
S1176 in mice), which is critical for increasing NO output from the
enzyme [165], is diminished in mice by nutrient excess [166–169]
or high-fat feeding [117,122,170,171]; studies in obese rats [172–
174] and pigs [175] show similar results. This NOS3 phosphoryla-
tion site can be regulated by Akt [176], which is activated by
insulin [177]. Insulin stimulation of the Akt–NOS3 pathway could
thus be important for regulating postprandial blood ﬂow and
nutrient disposition to peripheral tissues. Indeed, insulin resis-
tance in the endothelium is sufﬁcient to diminish NO bioavail-
ability and promote endothelial dysfunction [178], and impaired
NOS3 phosphorylation due to insulin resistance was shown to be
responsible for diminished glucose uptake in the skeletal muscle
of mice subjected to nutrient excess [179].
The diminished phosphorylation of NOS3 under conditions
of nutrient excess and obesity could be due to fatty acid (e.g.,
palmitate)-mediated induction of insulin resistance [117]. Elevated
free fatty acids (FFAs) lower NO bioavailability in cultured cells
[180], isolated arteries [181], animal models [182], and humans
[183,184], and this is probably due to decreased PI3K–Akt-
mediated activation of NOS3 [185]. Insulin resistance due to
FFAs may be engendered by activation of Toll-like receptor 4
(TLR4) and NF-κB [170,180] or TLR2 [186]. Other nutrient condi-
tions inherent to diabetes may also be responsible for loss of
S1177-NOS3 phosphorylation. For example, hyperglycemia causes
O-linked N-acetylglucosamine (O-GlcNAc) modiﬁcation of NOS3,
which diminishes its activity [187]. Other mechanisms posited for
diminished NOS3 phosphorylation in the context of obesity
include a fatty acid-mediated, yet Akt-independent, impairment
of NOS3 phosphorylation [171] and PKCβII-mediated diminish-
ment in Akt and NOS3 responsiveness to insulin [172,174].
Interestingly, insulin-sensitizing therapeutic agents have robust
effects on both NOS3 and NOS2. Several glitazone derivatives (also
known as thiazolidinediones) used to treat type 2 diabetes
increase NOS3 activity or expression in cultured endothelial cells
[188–191]. Furthermore, the anti-diabetes drug metformin was
shown to stimulate NOS3 activity in vitro and in vivo in an AMP
kinase-dependent and HSP90-mediated manner [192]. Conversely,
insulin-sensitizing PPAR-γ agonists robustly repress NOS2 expres-
sion in multiple cell and tissue types [193–198].
Uncoupling of NOS and quenching of NO in metabolic disease
The ability of NOS to produce NO is also dependent on its
proper coupling, which is regulated by multiple cofactors, the
ability of the NOS enzyme to remain in the dimerized form
[199,200], and posttranslational modiﬁcations [94,201–203]
(Fig. 2C). In particular, the cofactor BH4 is critical to NOS activity,
and it has been termed a “redox sensor” because elevations in
reactive oxygen and nitrogen species can result in its depletion
[204]. Furthermore, BH4 has been suggested to reﬂect the overall
“health” of the endothelium [205]. Obese and diabetic states in
rodents and human cells are associated with decreased BH4 and
elevated levels of its oxidized form, BH2 [205–209]. This is
important because deﬁciency in BH4 or elevations in BH2 can
uncouple NOS, which results in superoxide production from the
enzyme and increases peroxynitrite generation [201]. Hence,
deﬁciency of BH4 is thought to be a major regulator of vascular
dysfunction that occurs during obesity and in diabetic states.
Indeed, the ratio of BH4 to BH2 is critical in preventing glucose-
induced NOS3 uncoupling [210], and replenishment of BH4 pools
by either providing sepiapterin or inducing pathways that increase
biopterin synthesis or maintain BH4 in its reduced state has proven
effective in multiple pathological scenarios (for review, see
[201,202,211–213]). Uncoupling of NOS does not seem to be a
factor unique to NOS3, however, as NOS1 was shown to be
uncoupled in penile arteries of obese rats, leading to nitrergic
dysfunction, which was corrected by increasing BH4 levels [214].
Peroxynitrite may be especially critical in promoting NOS
uncoupling. 3-Nitrotyrosine (3-NT) is a typical “footprint” post-
translational modiﬁcation that helps identify the sites at which
NOS3 uncoupling might have occurred, and it is worth noting that
this modiﬁcation is observed in abundance in the context of
obesity and diabetes (e.g., [122,206,215,216]). Patients with dia-
betes had diminished ﬂow-mediated dilation of coronary arter-
ioles and increased 3-NT protein adducts that colocalized with
caveolae, demonstrating a dysfunction of the endothelium asso-
ciated with elevated peroxynitrite production [217]. Interestingly,
endothelial dysfunction in the diabetic patients was rescued by
sepiapterin supplementation [217], inferring that peroxynitrite
may disrupt NOS3 function not only by caveolar disruption, but
by depleting BH4. This would be consistent with multiple studies
showing that elevated levels of reactive species (in addition to
peroxynitrite, such as superoxide produced from NADPH oxidase)
promote NOS3 uncoupling [218–222]. Nevertheless, the speciﬁc
contribution of peroxynitrite and other reactive species to
endothelial function remains unclear, as other studies suggest that
rather than uncoupling NOS3, superoxide from NADPH oxidase
activates the enzyme; hence, inhibited NOS3 function perceived
under conditions of oxidative stress could be due in part to the
quenching of NO and not to uncoupling of the enzyme per se [223].
Although this would be consistent with the near-diffusion-limited
reaction rate of NO with superoxide (which is reported
to be as high as 1.91010 M1 s1) [224], the evidence for a
deleterious role of uncoupled NOS should not be underestimated,
and multiple other factors beyond BH4 depletion, such as asym-
metric dimethyl arginine (ADMA), insufﬁcient L-arginine levels, or
glutathio(ny)lation of the NOS3 enzyme, can promote NOS3
uncoupling and endothelial dysfunction [94,225–228]. That levels
of ADMA are positively correlated with insulin resistance and
diabetes and that arginine supplementation overcomes this com-
petitive inhibition [229] further suggest that losses in NOS3
coupling or activity are major contributors to the development of
metabolic diseases associated with obesity.
Despite these ﬁndings, it is unclear whether obesity itself
decreases NO availability. The fact that obesity in humans is
associated with decreased blood ﬂow in response to methacholine
[230], bradykinin [231,232], substance P and acetylcholine [232],
shear stress [233], and insulin [234,235] seems to suggest that the
obese condition is somehow linked causally with diminished
vascular NO bioavailability; a multitude of studies showing similar
results lends support to this hypothesis [120,236–247]. However,
the question remains: is loss of NO production somehow due to
excess adiposity, or is its etiology derived from those conditions
commonly associated with obesity? Interestingly, endothelial
dysfunction was found to occur in morbidly obese humans only
when insulin resistance was present [248]. And, severely obese
humans, in the absence of insulin resistance, showed better ﬂow-
mediated dilation compared with normal and obese insulin-
sensitive subjects [249]. Furthermore, capillary recruitment has
been shown to be higher in overweight compared with lean
individuals [250]. This suggests that the maintenance of a meta-
bolically benign form of obesity is possible and that either insulin
resistance or conditions directly linked with the insulin-resistant
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phenotype (e.g., dyslipidemia, inﬂammation, hyperglycemia) are
to blame for diminished NO bioavailability during obesity. Collec-
tively, these ﬁndings bring forth multiple questions: what deter-
mines how metabolically benign versus harmful forms of obesity
evolve? How does NO affect obesity and insulin resistance? And
what is the relevance of changes in NOS isoform abundance, some
of which go in diametrically opposite directions (e.g., NOS3 vs
NOS2), in the development of metabolic disease?
Regulation of obesity and insulin resistance by NO
Both pharmacological studies and gain-of-function and loss-of-
function studies have helped elucidate critical roles for NO in
regulating obesity and insulin resistance. To date, supplementation
with the NOS substrate L-arginine and inhibition of NOSs have
been the most common pharmacological approaches used to
determine how NO regulates body composition and insulin sensi-
tivity. Genetic approaches, utilizing mice in which components
integral to the synthesis of NO have been deleted or overex-
pressed, have further led to the development of a model
by which NO regulates systemic metabolism. The model is
complex and involves nearly all aspects thought to be important
in regulating metabolic homeostasis.
Lessons from pharmacological interventions
Early pharmacological studies, using primarily L-arginine and
NOS inhibitors, showed that NO is a potent regulator of both
energy intake and expenditure. Interestingly, both L-arginine and
inhibitors of NOS prevent obesity and insulin resistance, albeit by
different mechanisms.
NO increases food intake
In rodents, L-arginine was shown to increase, and NOS inhibitors
to decrease, food intake [155,251–254]. These effects were due to NO
activity in the brain, impinging on the leptin and serotonergic
systems that regulate hunger. Leptin, given intracranially, was found
to diminish diencephalic NOS activity and decrease food intake and
body weight gain, and intracranial coadministration of L-arginine
antagonized this effect [255]. Furthermore, intracerebroventricular
injection of L-arginine, probably through stimulation of NOS activity,
inhibited serotonin-induced anorexia caused by IL-1β [256]. Studies
with NOS inhibitors have further solidiﬁed our understanding of the
central effects of NO on hunger. Systemic administration of the NOS
inhibitor NG-nitro-L-arginine, reduced food intake in obese rats and
increased serotonin metabolism in the cortex, diencephalon, and
medulla pons, thereby implicating the central serotoninergic system
in mediating the anorexic effect of NOS inhibitors [257]. Other NOS
inhibitors, such as L-NAME, promote weight loss and diminish food
intake in ob/ob and db/db mice [253] and obese rats [258] as well as
reducing adiposity and improving insulin sensitivity in a high-fat-fed
mouse model [259]. Interestingly, intracerebroventricular adminis-
tration of NG-monomethyl-L-arginine was shown also to regulate
insulin secretion and peripheral insulin sensitivity [260], suggesting
that centrally derived NO has effects that extend to distal nodes of
systemic metabolism. It is also possible that this effect contributes to
the hyperphagic effects of NO, as insulin is well known to regulate
hunger and satiety [261–265]. Taken together with numerous other
studies demonstrating a role for NO in the regulation of hunger
[266–270], it would seem that NO produced in the brain antagonizes
anorectic signals and stimulates food intake.
NO increases energy expenditure and regulates glucose and lipid
metabolism
Ostensibly, this might imply that by promoting food intake,
increased levels of NO, e.g., those elicited by supplementation with
L-arginine, should increase adiposity and insulin resistance. How-
ever, human studies have repeatedly shown that L-arginine sup-
plementation has favorable effects on body composition and
insulin sensitivity [271–277]. Results from animal studies are in
general agreement: L-arginine has been shown to have multimodal
effects characterized by decreased fat mass, increased muscle
mass, and improved insulin sensitivity. Despite promoting hyper-
phagia, L-arginine feeding reduced white adipose tissue mass,
improved insulin sensitivity, and increased energy expenditure
in mice [278]. In rats, not only has dietary L-arginine supplemen-
tation been shown to reduce fat mass, but it appears to increase
skeletal muscle and brown fat mass and reduce serum concentra-
tions of glucose, triglycerides, free fatty acids, homocysteine,
dimethylarginines, and leptin as well [279,280]. Similar salubrious
systemic effects of L-arginine were demonstrated in pigs [281].
Overall, the collective data suggest that L-arginine, and by
inference, NO, has the capacity to reduce fat mass by increasing
mitochondrial biogenesis, regulating brown adipose tissue signal-
ing, and increasing the expression of genes that promote oxidation
of energy substrates [282].
Chronic treatment with sildenaﬁl, which prevents the degrada-
tion of cGMP and is commonly prescribed to improve erectile
function, improved insulin action and diminished obesity in high-
fat-fed mice [283]. Shorter durations of sildenaﬁl treatment were
shown to promote “browning” of white adipose tissue [284].
Although there are no reports of regulation of obesity in humans
by type 5-phosphodiesterase inhibitors such as sildenaﬁl, they
have been shown to increase mitochondrial biogenesis in human
adipose tissue ex vivo [285], suggesting at least the potential to
promote energy expenditure.
Other compounds that function in the NO pathway lend
additional support to a role for NO in regulating insulin sensitivity.
Restoration of NOS3 phosphorylation in endothelial-speciﬁc insu-
lin receptor substrate 2 (IRS-2)-knockout mice using beraprost
(a stable prostaglandin analog) was sufﬁcient to rescue capillary
recruitment and to promote adequate insulin and glucose delivery
to skeletal muscle [179]. Insulin, L-arginine, and sodium nitroprus-
side, by promoting S-nitro(sy)lation of key proteins, were shown
to be particularly critical for regulating vascular endothelial insulin
uptake and its transendothelial transport [286]. Hence, NO derived
from NOS3 appears to be pivotal for regulating systemic glucose
metabolism and insulin delivery to peripheral tissues.
As has been a theme with NO, its effects depend on its site of
generation, concentration, and duration of application. Particularly
interesting are its modes of action in the liver, skeletal muscle, and
pancreas. Although chronic treatment with NOS inhibitors promotes
weight loss and insulin sensitivity in animal models [253,258,259],
acute applications of inhibitors of NOS cause systemic insulin resis-
tance [287]. This, in part, is mediated by actions in the liver, which can
regulate systemic responses to insulin [288]. Administration of BH4,
which is known to be oxidized to BH2 in the diabetic state [289–291]
and plays an important role in regulating coupled NOS3 activity (vide
supra), to STZ-induced diabetic mice lowered fasting blood glucose
levels in an NOS3-dependent manner and improved glucose tolerance
and insulin sensitivity in ob/ob mice [292]. This metabolic improve-
ment was at least partially due to NOS3-mediated activation of
AMPK in the liver, which suppressed hepatic gluconeogenesis [292].
Hence, the activity of NOS3 uncoupling in liver may be important for
regulating systemic glucose metabolism.
Other studies also demonstrate an important role for liver
NOS3 and nitrogen oxides. For example, intraportal administration
of NOS inhibitors was shown to cause insulin resistance, which
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was rescued by intraportal delivery of the NO and superoxide
donor SIN-1 [293,294]. Interestingly, when liver glutathione was
ﬁrst depleted by buthionine sulfoximine, the effects could not be
rescued by sodium nitroprusside or SIN-1 [294]. These results
suggest that nitrosated glutathione might be important in max-
imizing liver-mediated systemic responses to insulin. That intra-
portal delivery of glutathione methyl ester and SIN-1 enhances
insulin sensitivity in rats would seem to support this hypothesis
[295].
The NO–HISS connection?
This adds an additional question: how does NO (and its
oxidation products) in the liver mediate systemic responses to
insulin? The answer has been suggested to lie in a hormone called
“hepatic insulin-sensitizing substance” (HISS). This substance, for
which there are only suggestive candidates (e.g., bone morphoge-
netic protein-9 [296]), has been suggested to account for 55% of
the glucose disposal effect of insulin. Brieﬂy, it is posited that
postprandial elevations in insulin result in release of a hormone,
i.e., HISS, from the liver that acts on skeletal muscle to promote
glucose uptake [297,298]. Intriguingly, one study suggests that
HISS, not insulin action, regulates the peripheral vasodilation
generally attributed to insulin [299]. Atropine or hepatic surgical
denervation inhibited the peripheral vascular actions of insulin,
allegedly by blocking HISS release, and intraportal delivery of
acetylcholine, which increases NOS activity, restored HISS release
and insulin-mediated vasodilation [299]. This is consistent with
original studies showing that insulin-mediated vasodilation is
dependent on NO [300,301] and that insulin-mediated skeletal
muscle vasodilation contributes to insulin sensitivity in humans
[302]; and, combined with other studies suggesting a role for NO
in promoting release of HISS [303–305], this suggests that the
putative hormone could be an NO-regulated, liver-produced,
endocrine mediator of classical EDRF important for glucose dis-
posal. What remains to be elucidated (in addition to the identity of
HISS) is how this distally engendered mode of vasoregulation
integrates physiologically (and pathologically) with the known
local effects of insulin and NO in the vasculature [176–179].
Pancreatic effects of NO
Extremely important for maintaining metabolic homeostasis,
the pancreas also utilizes NO to regulate its function. Brieﬂy, the
pancreas comprises two types of glands: (1) exocrine glands,
which secrete the bicarbonate and digestive enzymes needed to
neutralize the acidic gastric contents entering the small intestine
and to complete digestion of food, respectively, and (2) endocrine
glands, i.e., the islets of Langerhans, which contain several types of
secretory cells, including α cells, β cells, δ cells, and F cells. Each of
these cells secretes multiple proteins, such as insulin (β cells),
glucagon (α cells), and somatostatin (δ cells). NO has been shown
to affect both exocrine and endocrine functions of the pancreas.
The effects of NO on the exocrine actions of the pancreas can be
found in [306,307].
With respect to insulin release, it seems that NO stimulates
early, glucose-induced insulin release, whereas it is responsible for
cytokine (e.g., IL-1β)-mediated inhibition of insulin secretion. This
dual role of NO in regulating insulin secretion has been the subject
of controversy (e.g., [308]), which might be based, in part, on the
mechanistic complexity regulating pancreatic insulin secretion
and is probably compounded by the multiple actions of NO. The
inhibitory actions of NO on insulin release appear to be due to
NOS2-derived NO, which is implicated in the destruction of islet
cells in type 1 diabetes [309,310]. The mechanisms regulating the
insulin-stimulating effects of NO [311–314] have been more
difﬁcult to elucidate. However, NO is suggested to stimulate islet
cell insulin secretion by inducing calcium release from mitochon-
dria [315], which may be due to NO-mediated inhibition of
respiration and mitochondrial depolarization. Nevertheless, the
stimulatory effects of NO on insulin secretion are relatively subtle
[314], which might explain why other studies suggest that NO is
not involved in the initiation of insulin secretion from pancreatic
islets [316,317].
Lessons from human studies and genetic interventions
Considerable data have accumulated suggesting an association
between genetic polymorphisms in NOS isoforms and insulin
resistance. Most notably, several studies have associated a T
(786)C variant of the NOS3 gene with insulin resistance [318–
320]. Several other genetic variants in the NOS3 locus are
associated with T2D [321], susceptibility for insulin resistance,
hypertriglyceridemia, and low HDL [322] or worsened endothelial
function in individuals prone to T2D [323]. Polymorphisms in the
NOS2 gene have been associated with higher plasma glucose and
elevated waist/hip ratios [324], and variants in the NOS2 gene
promoter were found to be associated with T2D [325].
Genetic manipulation of NOS isoforms in mice have allowed for
interrogation of the mechanisms by which NO regulates metabolic
health and disease. In mice, deletion of NOS3 causes insulin
resistance, hyperlipidemia, and hypertension [326]. Whereas full
gene deletion mimics human “metabolic syndrome,” even partial
gene deletion of NOS3 results in exaggerated insulin resistance,
glucose intolerance, and hypertension induced by high-fat feeding
[327,328]. A study using NOS3/NOS1 double-knockout mice
showed that deletion of NOS3 promotes insulin resistance in both
skeletal muscle and liver, whereas NOS1 deletion impairs insulin
sensitivity only in liver [329]. Mice lacking all isoforms of NOS, i.e.,
NOS3/NOS1/NOS2 triple-knockout mice, demonstrate increased
visceral obesity, hypertension, hypertriglyceridemia, and impaired
glucose tolerance, and, it is interesting to note, this is one of the
few mouse strains to date to have spontaneous myocardial infarc-
tions, apparently due to unstable coronary arteriosclerotic lesions
[330]. That NOS is important in regulating insulin sensitivity was
further shown by studies in mice in which overexpression of
dimethylarginine dimethylaminohydrolase—an enzyme that cata-
lyzes the breakdown of the endogenous inhibitor of NOS, ADMA—
increased insulin sensitivity [331].
Antiobesogenic effects of NOS3
It seems that the metabolic phenotype elicited by insufﬁcient
levels of NOS3-derived NO relates directly to defects in intermedi-
ary metabolism in key peripheral tissues. Supporting evidence
supplied by NOS3-KO mice include markedly lower energy expen-
diture and decreases in mitochondrial content and fatty acid
oxidation in muscle compared with wild-type mice [332]; and, as
expected, NOS3-KO mice demonstrate an impaired ability to
exercise [333]. Gain-of-function studies show a remarkable ability
of NOS3 to regulate body composition and increase metabolism.
Supplementation of NOS3-KO mice with nitrate, which can be
serially reduced to nitrite and NO, reduced not only blood pressure,
but visceral fat and triglycerides as well, thus reversing features of
metabolic syndrome [334]. Furthermore, mice overexpressing NOS3
show an antiobesogenic phenotype characterized by resistance to
accumulation of white adipose tissue in response to a high-fat diet,
a higher metabolic rate, resistance to diet-induced hyperinsuline-
mia, and remarkably lower plasma levels of free fatty acids and
triglycerides [122]. Similar results were obtained in a NOS3 phos-
phomimetic point mutant mouse model [335,336]. Mutation of
serine 1176 of NOS3 to an aspartic acid resulted in increased
endothelial NO production as well as resistance to diet-induced
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weight gain and hyperinsulinemia; mutation of the residue to an
alanine, which cannot be phosphorylated, resulted in insulin
resistance and features of metabolic syndrome [157,336].
How does NOS3 regulate metabolism and body composition?
Several possibilities exist. Consistent changes in plasma lipids
insinuate a central role of NOS3 in lipid oxidation or synthesis,
e.g., NOS3 KO mice have elevated plasma levels of triglycerides and
free fatty acids compared with wild-type mice [326,328], whereas
NOS3 transgenic mice show diminished abundance of these lipids
[122]. That these differences are due to modulation of fat oxidation
capacity is suggested by studies showing a direct effect of NO on the
capacity to oxidize fat. Not only do NOS3-KO mice show diminished
fat oxidation capacity in skeletal muscle [332], but administration of
a NOS inhibitor is sufﬁcient to increase serum triglycerides and
diminish hepatic fatty acid oxidation in rats [337], potentially by
decreasing the activity of carnitine palmitoyl transferase [338].
Similarly, NOS inhibitor-dependent decreases in fat oxidation
capacity occur in heart tissue [339]. In isolated hepatocytes, treat-
ment with NO donors was shown to increase fatty acid oxidation in
a cGMP-dependent manner by inhibiting acetyl-CoA carboxylase
(thereby decreasing production of malonyl-CoA) and by stimulating
carnitine palmitoyl transferase activity [340]. Interestingly, NO also
inhibits fatty acid synthesis in hepatocytes [340], which is consis-
tent with studies showing that NOS inhibitors [341] or genetic
deletion of NOS3 increases lipid synthesis in liver [342]. In skeletal
muscle, genetic deletion of NOS3 increases neolipogenic gene
expression while downregulating genes involved in β-oxidation
[332].
That genes involved in fatty acid oxidation are modulated by NO is
consistent with data showing that overexpression of NOS3 increases
expression of PPAR-α [122], which is well known to regulate lipid
metabolism [343]. However, it is possible that NO regulates fat
oxidation posttranslationally as well. Recent studies show widespread
S-nitrosation of multiple enzymes involved in intermediary metabo-
lism. In particular, the liver enzyme very long chain acyl-CoA dehy-
drogenase was shown to be nitrosated at Cys238, which increased the
catalytic efﬁciency of the enzyme, and this modiﬁcation was absent
in NOS3-KO mice [344]. Collectively, these studies suggest that the
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Fig. 3. Working model of the systemic effects of NO on obesity and metabolism. The major organs and processes affected by NO and nitrogen oxides derived from NOS3,
NOS1, and NOS2 are illustrated. The NOS3 isoform shows antiobesogenic and insulin-sensitizing effects, which seem to be based on the ability of the enzyme to decrease
lipid synthesis and promote fat oxidation in the liver and skeletal muscle. Additionally, NOS3 may be implicated in the secretion of hepatic insulin sensitizing substance
(HISS), which might support insulin sensitivity in peripheral tissues such as skeletal muscle. NOS3 is important also for maximizing delivery of insulin and substrates to
skeletal muscle, and this is critical in regulating insulin sensitivity and glucose tolerance. Through its actions in liver and pancreas, NOS3 may also suppress gluconeogenesis
and prevent hyperinsulinemia, respectively. Additionally, NO increases the abundance of mitochondria and stimulates substrate oxidation capacity in adipose tissue,
effectively promoting “browning” of white adipocytes. Conversely, other isoforms of NOS appear to have a more malevolent role in metabolism. NO derived from NOS1
promotes hyperphagia, and NOS2-derived nitrogen oxides can promote insulin resistance and inﬂammation in key peripheral tissues such as liver, skeletal muscle, and
adipose tissue. In addition, NOS2 may affect glucose homeostasis by increasing glucose output from the liver and by impairing the endocrine activities of the pancreas.
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powerful antiobesity effects of NOS3-derived NO could be due to
simultaneous increases and decreases in fat oxidation and synthesis,
respectively.
NOS2 promotes insulin resistance
NO and RNS generated from the NOS2 enzyme could also
regulate systemic metabolism. Most profound are its effects on
insulin resistance. Although ablation of the NOS2 gene has no
effect on weight gain, its absence was shown to improve glucose
tolerance, normalize insulin sensitivity, and prevent derangements
in PI3K–Akt signaling in high-fat-fed mice [345]. Commonly,
increases in NOS2 expression in skeletal muscle of obese mice
are associated with increased S-nitrosation of the insulin receptor
(IR), IRS-1, and Akt, suggesting that nitrosative posttranslational
modiﬁcations of proteins in the insulin signaling pathway are
responsible for NOS2-induced insulin resistance [346,347]. The
presence of NOS2 seems to decrease the abundance of IRS-1 by
promoting its proteasomal degradation [148]. Interestingly, an
acute bout of exercise was sufﬁcient to downregulate NOS2 in
high-fat-fed rats as well as prevent S-nitrosation of proteins
involved in insulin signaling, and administration of an inhibitor
of NOS2 (L-N6-(1-iminoethyl)lysine; L-NIL) phenocopied these
effects [348]. Also, aspirin—which is one of the oldest known
treatments for diabetes [349,350] and improves blood glucose and
insulin sensitivity in diabetic patients [351] and animal models of
T2D [352]—inhibited NOS2-mediated S-nitrosation of IR, IRS-1,
and Akt in skeletal muscle and improved insulin sensitivity [353].
In other tissues, NOS2 expression is also important for regulat-
ing insulin sensitivity. Selective overexpression of NOS2 in liver is
sufﬁcient to cause hepatic insulin resistance, hyperglycemia, and
hyperinsulinemia [354], and the use of a NOS2-speciﬁc inhibitor
(L-NIL) reversed hyperglycemia, hyperinsulinemia, and insulin
resistance in ob/ob mice [150]. In obesity, proinﬂammatory macro-
phages accumulating in adipose tissue are responsible for the
majority of NOS2 expression [151–153] and may propagate the
inﬂammatory signaling implicated in insulin resistance [130].
Importantly, the role of NOS2 in adipose tissue appears to differ
remarkably from the canonical NO–cGMP pathway, as diet-
induced increases in proinﬂammatory cytokines and macrophage
recruitment were attenuated by administration of sildenaﬁl [355].
Interestingly, lack of NOS2 does not prevent age-induced insulin
resistance [356], which suggests that not all insulin-resistant
states are created equal [357]. In line with this, mice lacking the
NOS1 isoform show insulin resistance that appears to be due to a
sympathetic, α-adrenergic mechanism [358].
Summary
Integration of results from these studies helps to form a model
illustrating the role of NO in regulating obesity and insulin
resistance (Fig. 3). NO derived from NOS3 appears to have both
antiobesogenic and insulin-sensitizing properties. Its antiobeso-
genic role stems from its ability to increase fat oxidation in
peripheral tissues such as skeletal muscle, liver, and adipose tissue.
As mentioned above, there is evidence that it also decreases lipid
synthesis in liver. The impact of NOS3 on glucose metabolism and
insulin sensitivity is underpinned by its capacity to increase
transport of insulin and glucose to key peripheral tissues such as
skeletal muscle and to regulate gluconeogenesis. Additionally,
there may be implications for NOS3-mediated HISS release, which
appears to enhance the vasodilatory properties of insulin. That
NOS3 prevents hyperinsulinemia in two independent genetic
gain-of-function studies [122,336] further suggests that it could
have an impact on glucose metabolism by modulating insulin
release. Other isoforms of NOS appear to promote deleterious
changes in metabolism. In the brain, evidence suggests that
NOS1-derived NO promotes hyperphagia. The NOS2 isoform
promotes insulin resistance in both liver and skeletal muscle and
is critical in inﬂammatory responses in multiple tissues, most
notably, the adipose organ. Counter to NOS3, NOS2 appears to
promote gluconeogenesis, and NOS2 has remarkable effects on
cytokine-mediated insulin secretion. From these studies, it is
apparent that NO is one of the most critical features regulating
metabolism, body composition, and insulin sensitivity. Harnessing
its beneﬁcial metabolic actions is an exciting prospect for combat-
ting metabolic disease.
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